-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Resolvine ER in Vitreomacular Adhesion (VMA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Resolvine ER in Vitreomacular Adhesion (VMA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Resolvine ER in Vitreomacular Adhesion (VMA)Drug Details:Resolvine is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Neratinib in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Neratinib in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Neratinib in Solid Tumor Drug Details:Neratinib (Nerlynx) is a member of the 4-anilino...
-
Product Insights
MoME Serbia – VMA Hospital Renovation – Central Serbia
Equip yourself with the essential tools needed to make informed and profitable decisions with our MoME Serbia - VMA Hospital Renovation - Central Serbia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Company Profile
Oxurion NV – Company Profile
Oxurion NV (Oxurion), formerly ThromboGenics NV, is a biotechnology company, which develops and commercializes ophthalmic and cancer therapeutics. The company’s ocriplasmin, a recombinant derivative of the plasmin protein, is commercialized as Jetrea in the US to treat symptomatic vitreomacular adhesion (VMA) and vitreomacular traction (VMT). Oxurion’s product pipeline includes THR-687, a pan-RGD integrin antagonist being developed for the treatment of diabetic retinopathy, and THR-149, a plasma kallikrein inhibitor, for the treatment of diabetic macular edema (DME). It has commercialization agreements...
Add to Basket -
Product Insights
Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2018
GlobalData's clinical trial report, “Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2018" provides an overview of Vitreomacular Adhesion (VMA) clinical trials scenario. This report provides top line data relating to the clinical trials on Vitreomacular Adhesion (VMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Vitreomacular Adhesion (VMA) Global Clinical Trials Review, H2, 2016" provides an overview of Vitreomacular Adhesion (VMA) clinical trials scenario. This report provides top line data relating to the clinical trials on Vitreomacular Adhesion (VMA). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...